Product

Metoclopramide-Darnitsa

1 form: solution. In force in Georgia: 1 of 1 (human register).

Forms and doses1 of 1 in force in Georgia

Form	Dose	Frequency	Georgia
5 mg/ml, Solution	No label dose in the reference yet	-	Georgia Yes, human In force until 18 Mar 2027 Human (Ministry of Health, RAMA) In the register: მეტოკლოპრამიდი-დარნიცა 5 მგ/მლ, 2 მლ ამპულა № რ-034702 mis.ge (Ministry of Health register incl. past registrations) Verified on: 16 Oct 2026
Details: pack, label wording, sources, registration Metoclopramide-Darnitsa 5 mg/ml, Solution 2 ml ampoule, human medicine vetman assessment vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient. Dog Short-term off-label metoclopramide by IV or IM route as an upper-GI prokinetic and secondary antiemetic for selected non-obstructive nausea, vomiting or delayed gastric emptying in dogs 6.4/10 Situational / acceptable vetman assessment Metoclopramide-Darnitsa 5 mg/ml, 2 ml ampoule, human medicine Assessed clinical scopeDog · Short-term off-label metoclopramide by IV or IM route as an upper-GI prokinetic and secondary antiemetic for selected non-obstructive nausea, vomiting or delayed gastric emptying in dogs · IV,IM Care settingClinic or hospital use after obstruction and perforation have been excluded; bolus or repeated treatment is selected and monitored by the veterinary team vetman score 6.4/10 Situational / acceptable Evidence confidence: Medium Georgia: Yes, human · № რ-034702 · Verified on 16 Oct 2026 Off-label use A situational off-label hospital option when upper-GI dysmotility is part of the problem and obstruction is excluded. It is less reliable as a stand-alone broad antiemetic than newer agents, but the 5 mg/ml ampoule supports accurate IV/IM dosing and monitored short-term use. Regulatory and scientific credibility6.0/10 The exact human ampoule has a sourced current Georgian registration and identifiable manufacturer, strength and IV/IM route. Exhaustive checked EU/EEA, UK and US registers contained no exact trade-name match; it has no veterinary authorisation and animal use is off-label. Clinical efficacy6.5/10 Canine evidence supports upper-GI prokinetic activity and benefit in an experimental postoperative-ileus model; a small prospective parvoviral study also found reduced vomiting. However, a blinded low-dose cisplatin crossover found no anti-nausea or antiemetic effect, and efficacy is less consistent and less broadly acting than newer antiemetics. Safety and tolerability6.0/10 Short-term veterinary use is usually manageable, but these exact human products have no dog- or cat-specific safety dossier. Dopamine antagonism can cause agitation, disorientation, sedation, tremor, dystonia, seizures or rare neuroleptic malignant syndrome; renal or hepatic impairment, interacting CNS drugs and cumulative exposure require review. Clinical practicality7.5/10 The 5 mg/ml, 2 ml ampoule permits accurate weight-based IV or IM dosing in hospital. Repeated q6-8h administration or a CRI still requires staff time, asepsis, venous access when applicable and neurologic monitoring; this exact human ampoule is not recorded for veterinary SC use. Full-course cost-effectiveness- Price was not assessed and is excluded from the overall score. Important safety and use flags Do not use a prokinetic when gastrointestinal obstruction, perforation or haemorrhage is suspected or confirmed; exclude a mechanical cause before symptom suppression. Avoid in epilepsy or uncontrolled seizure disease and after a serious dystonic or extrapyramidal reaction to metoclopramide; dopamine antagonism can worsen these problems. Avoid or closely review concurrent phenothiazines, antipsychotics and other dopamine antagonists because sedation, dystonia, extrapyramidal signs and neuroleptic malignant syndrome may be additive. Anticholinergic drugs and opioids can oppose the intended motility effect; reassess whether metoclopramide remains useful and monitor sedation and bowel function. Review serotonergic medicines, monoamine-oxidase inhibitors and strong CYP2D6 inhibitors. Monitor agitation, tremor, hyperthermia, autonomic instability or hypertension and stop and reassess if toxicity is suspected. Renal impairment can increase exposure, and severe hepatic disease may reduce clearance. Reconsider dose or interval and monitor neurologic effects in organ-impaired patients. Stop and reassess for new agitation, disorientation, abnormal movements, tremor, rigidity, hyperthermia or autonomic instability. Keep treatment as short as clinically justified because neurologic risk rises with cumulative exposure. Give IV boluses slowly and follow aseptic single-use ampoule practice. This exact human presentation is recorded for IV/IM use; do not infer that general veterinary SC guidance authorises the SC route for this ampoule. Assessment sources Metoclopramide market audit2026 FDA Reglan injection label2026 Merck Vet Manual prokinetics2026 Merck Vet Manual antiemetics2026 Dog cisplatin antiemetic crossover2017 Dog parvoviral emesis study2017 Dog postoperative ileus study1989 Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised. Cat Short-term off-label metoclopramide by IV or IM route as an upper-GI prokinetic and secondary antiemetic for selected non-obstructive nausea, vomiting or delayed gastric emptying in cats 6.1/10 Situational / acceptable vetman assessment Metoclopramide-Darnitsa 5 mg/ml, 2 ml ampoule, human medicine Assessed clinical scopeCat · Short-term off-label metoclopramide by IV or IM route as an upper-GI prokinetic and secondary antiemetic for selected non-obstructive nausea, vomiting or delayed gastric emptying in cats · IV,IM Care settingClinic or hospital use after obstruction and perforation have been excluded; bolus or repeated treatment is selected and monitored by the veterinary team vetman score 6.1/10 Situational / acceptable Evidence confidence: Medium Georgia: Yes, human · № რ-034702 · Verified on 16 Oct 2026 Off-label use A situational feline prokinetic with direct gastric-emptying evidence, but a comparatively weak stand-alone antiemetic. The 5 mg/ml ampoule is accurately measurable; exclude obstruction, monitor neurologic effects and treat the underlying cause rather than escalating symptom control blindly. Regulatory and scientific credibility6.0/10 The exact human ampoule has a sourced current Georgian registration and identifiable manufacturer, strength and IV/IM route. Exhaustive checked EU/EEA, UK and US registers contained no exact trade-name match; it has no veterinary authorisation and animal use is off-label. Clinical efficacy5.5/10 A randomized double-blind crossover in eight healthy cats found faster solid gastric emptying and increased antral motility, supporting a prokinetic role. Feline antiemetic evidence is sparse and low-certainty, dopamine-mediated emesis is less important in cats, and benefit should not be generalized to every vomiting syndrome. Safety and tolerability6.0/10 Short-term veterinary use is usually manageable, but these exact human products have no dog- or cat-specific safety dossier. Dopamine antagonism can cause agitation, disorientation, sedation, tremor, dystonia, seizures or rare neuroleptic malignant syndrome; renal or hepatic impairment, interacting CNS drugs and cumulative exposure require review. Clinical practicality7.5/10 The 5 mg/ml, 2 ml ampoule permits accurate weight-based IV or IM dosing in hospital. Repeated q6-8h administration or a CRI still requires staff time, asepsis, venous access when applicable and neurologic monitoring; this exact human ampoule is not recorded for veterinary SC use. Full-course cost-effectiveness- Price was not assessed and is excluded from the overall score. Important safety and use flags Do not use a prokinetic when gastrointestinal obstruction, perforation or haemorrhage is suspected or confirmed; exclude a mechanical cause before symptom suppression. Avoid in epilepsy or uncontrolled seizure disease and after a serious dystonic or extrapyramidal reaction to metoclopramide; dopamine antagonism can worsen these problems. Avoid or closely review concurrent phenothiazines, antipsychotics and other dopamine antagonists because sedation, dystonia, extrapyramidal signs and neuroleptic malignant syndrome may be additive. Anticholinergic drugs and opioids can oppose the intended motility effect; reassess whether metoclopramide remains useful and monitor sedation and bowel function. Review serotonergic medicines, monoamine-oxidase inhibitors and strong CYP2D6 inhibitors. Monitor agitation, tremor, hyperthermia, autonomic instability or hypertension and stop and reassess if toxicity is suspected. Renal impairment can increase exposure, and severe hepatic disease may reduce clearance. Reconsider dose or interval and monitor neurologic effects in organ-impaired patients. Stop and reassess for new agitation, disorientation, abnormal movements, tremor, rigidity, hyperthermia or autonomic instability. Keep treatment as short as clinically justified because neurologic risk rises with cumulative exposure. Give IV boluses slowly and follow aseptic single-use ampoule practice. This exact human presentation is recorded for IV/IM use; do not infer that general veterinary SC guidance authorises the SC route for this ampoule. Assessment sources Metoclopramide market audit2026 FDA Reglan injection label2026 Merck Vet Manual prokinetics2026 Merck Vet Manual antiemetics2026 Feline antiemetic systematic review2026 Feline gastric-emptying crossover2020 ISFM inappetent cat guideline2022 Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised. Composition / strength Metoclopramide5 mg/ml Formulation Type Solution Administration route Intravenous, Intramuscular Manufacturer Darnitsa · Ukraine Registration Georgia Yes, human In force until 18 Mar 2027 Human (Ministry of Health, RAMA) In the register: მეტოკლოპრამიდი-დარნიცა 5 მგ/მლ, 2 მლ ამპულა № რ-034702 mis.ge (Ministry of Health register incl. past registrations) Verified on: 16 Oct 2026 EU No EMA Article 57 database (all medicines authorised in the EU/EEA), 09.10.2026 Verified on: 16 Oct 2026 UK No MHRA Products (UK) Verified on: 16 Oct 2026 US No Drugs@FDA (openFDA) Verified on: 16 Oct 2026 Controlled in Georgia No Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n. matsne.gov.ge Verified on: 16 Oct 2026

Active substance doses, with sources

Each dose comes with its source. Check the label of the product you use.

Active substance Metoclopramide

Dose calculatorCalculates the active-substance amount; it is not a prescription.

PatientSpecies and weight will be filled in automatically in other calculators.

Species Weight (kg)

Indication

Selected dose

Product presentation

Dose	Species	Indication	Route	Frequency	Source
0.25–0.5 mg/kg	Dog, Cat	Reduced Gastrointestinal Motility; Vomiting	By mouth / Intravenous / Intramuscular / Subcutaneous	2 times daily	VMD SPC 2025 Official product label (SPC), VMD, UK Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there. Emeprid 1 mg/ml oral solution for dogs and cats - Summary of Product Characteristics UK Veterinary Medicines Directorate, Product Information Database, 2025 Open the source ↗ VMD SPC 2025 Official product label (SPC), VMD, UK Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there. Emeprid 5 mg/ml solution for injection for dogs and cats - Summary of Product Characteristics UK Veterinary Medicines Directorate, Product Information Database, 2025 Open the source ↗
0.5 mg/kg	Dog, Cat	Vomiting	Intramuscular / Subcutaneous	every 6-8 hours	VMD SPC 2025 Official product label (SPC), VMD, UK Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there. Vomend 5 mg/ml solution for injection for dogs and cats - Summary of Product Characteristics UK Veterinary Medicines Directorate, Product Information Database, 2025 Open the source ↗

Known Contraindications

Critical
Do not use metoclopramide in patients with gastrointestinal perforation or obstruction. Its prokinetic action can worsen these conditions.

Sources: Product label
Critical
Do not use metoclopramide in patients with gastrointestinal haemorrhage.

Sources: Product label
Critical
Known hypersensitivity to the active substance or any excipient is an absolute contraindication on all four reviewed labels. The injectable Emeprid formulation contains metacresol (2 mg/mL) as an excipient.

Sources: Product label
Warning
Avoid metoclopramide in animals with epilepsy, other seizure disorders, or head trauma because it crosses the blood-brain barrier and may lower the seizure threshold.

Sources: Product label
Warning
Reduce or otherwise adjust the metoclopramide dose in renal insufficiency because accumulation increases the risk of adverse effects, including extrapyramidal reactions. The product labels do not specify a fixed reduction percentage.

Sources: Product label
Warning
Reduce the dose in hepatic impairment, as recommended for renal impairment. Metoclopramide is metabolized in the liver.
Warning
Do not use metoclopramide in animals with pheochromocytoma because it may provoke a hypertensive crisis.

Sources: Product label
Warning
Measure metoclopramide doses especially carefully in cats and small-breed dogs. Severe extrapyramidal or other neurological reactions are very rare but may require medical treatment.

Sources: Product label
Warning
Safety of metoclopramide in the target species during pregnancy and lactation has not been established. Use only after a veterinarian has assessed the individual benefit and risk.

Sources: Product label
Warning
After prolonged vomiting, consider fluid and electrolyte replacement. Metoclopramide controls the symptom but does not treat dehydration.

Sources: Product label
Warning (Dog)
Avoid metoclopramide in dogs with pseudopregnancy because dopamine D2 antagonism increases prolactin and may worsen clinical signs.

Sources: Product label

Known Drug Interactions

Major warning Acepromazine + Metoclopramide
Concomitant use with phenothiazine neuroleptics such as acepromazine or with butyrophenones increases the risk of extrapyramidal effects: agitation, ataxia, tremor, abnormal movements, vocalization, and aggression. Both agents block D2 receptors, producing an additive effect.

Recommendation: Avoid the combination where possible. If necessary, use the lowest metoclopramide dose and monitor the animal. Effects are transient and resolve after treatment stops; there is no specific antidote, and a quiet environment is recommended.
Minor warning Metoclopramide + Atropine
In animals with gastritis, avoid giving anticholinergic drugs such as atropine with metoclopramide because they can oppose its effect on gastrointestinal motility.

Recommendation: Avoid the combination in gastritis because the anticholinergic can oppose metoclopramide. Concomitant diarrhoea alone is not a contraindication to anticholinergic treatment.

Sources: Product label

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 16 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Metoclopramide-Darnitsa

Forms and doses1 of 1 in force in Georgia